Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Alexion Pharmaceuticals

Evaluate

Thumbnail
April 13, 2023

Zealand seeks deals in obesity and beyond

With Boehringer locked in, the Danish biotech wants more partners for monotherapies, combos and more.

Thumbnail
September 16, 2022

Astrazeneca pulls ahead in haemoglobinuria

Article image
Vantage logo
November 18, 2021

Novo’s $3.3bn GalXC quest

The usually conservative group spends big on Dicerna – but others might be interested too.

Article image
Vantage logo
July 21, 2021

Biopharma throws grease on the deal wheels

Company takeovers with promises of more cash down the road ticked up this year, a new Evaluate Vantage analysis finds.

Article image
Vantage logo
June 28, 2021

Key third-quarter readouts for big pharma

Abbvie expects more Rinvoq data in ulcerative colitis while Astrazeneca takes on myasthenia gravis, and gene therapy is in play for Pfizer and Roche.

Article image
Vantage logo
May 18, 2021

Bristol’s buy moves it to the top of the sales charts

The addition of Celgene made Bristol’s sales team pharma’s most productive last year on one measure, but the accolade might be short-lived.

Article image
Vantage logo
May 17, 2021

Apellis crosses the finish line – now to pay it back

Article image
Vantage logo
April 13, 2021

Quiet times return for biopharma takeouts

The first quarter of 2021 saw fewer deals than any in recent memory.

Article image
Vantage logo
March 22, 2021

Biocryst joins the push against Soliris

Article image
Vantage logo
March 17, 2021

Fresh antitrust push hits biopharma

Evaluate Vantage takes a look at the still-open deals that might come under threat from a new international clampdown.

Article image
Vantage logo
March 05, 2021

Apellis fails to complement severe Covid-19

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up